) options ahead of good news on the biopharmaceutical company’s COVID-19 drug treatment may draw regulatory scrutiny, experts said.
Those gains were dwarfed by a price jump in bullish options which traded in unusually high volume just hours before the report and which more than doubled in value overnight. Early in the trading day on April 16, with Gilead shares hovering around $75, four large blocks of its options were purchased for about $1.5 million each. Those unusually large trades bet that Gilead’s shares would rise north of $80 to $87.50 by mid August.
“When there is a specific spike in the firm’s trading activity — right before a finding is announced — it can become a red flag to regulators,” he said.
RemoveGOPNow Many bad actors are making money off the pandemic and not donating it back to the country.
Noooooo shit!
Blue Horseshoe loves Anacott Steel
RealTianZeng
¿Remdesivir... singing victory...? Not so soon......vaccines ready at all.......
That's what happens when you trust Gilead. HandmaidTale
SOLTARAM OS PRESOS PARA TOCAR O TERROR. ENTENDERAM AGORA ? Somos57MILHOES
Scumbags